GLP-1s offer a rare insight into the social and economic effects of carrying extra weight
Catch up on global daily news
Compelling long reads
Tune into captivating conversations
Watch engaging short films
Behind the scenes at The Economist
Possibly. But only under medical supervision
A handpicked article read aloud from the latest issue of The Economist
The expiry of patents in China, India and elsewhere will boost uptake dramatically
GLP-1 receptor agonists like semaglutide are being used off-label by healthy people hoping to slow ageing, despite limited…
Declaring it always a disease means millions will get treatment they may not need, writes Francesco Rubino
New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective and…
